Shares of CV Therapeutics Inc. rose 17.6 percent Wednesday on news that the firm received $175 million in cash from New York-based investment firm TPG-Axon Capital in exchange for rights to 50 percent of royalties on North American sales of Lexiscan (regadenoson) injection. (BioWorld Today) Read More
